Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Pharmacologic Inhibition of STK19 Impairs NRAS-Driven Melanoma

DOI: 10.1158/2159-8290.CD-RW2019-017 Published April 2019
  • Article
  • Info & Metrics
Loading
  • Major finding: Phosphorylation of oncogenic NRAS by STK19 promotes melanomagenesis.

  • Mechanism: Activation of NRAS mutants is enhanced by STK19-induced phosphorylation of NRAS at S89.

  • Impact: STK19 inhibition may provide a therapeutic strategy against melanomas harboring mutant NRAS.

Oncogenic mutations in RAS proteins occur in 20% to 30% of all human tumors. Mutations in NRAS at Q61 occur primarily in melanoma and trap NRAS in a constitutively active conformation. Despite the development of effective therapies against mutant BRAF–driven melanoma, no selective inhibitors of NRAS have been identified. Yin, Zhu, Zhang, Liu, and colleagues screened a kinome-wide siRNA library and identified the kinase STK19 as a regulator of NRAS activity. Depletion of STK19 in human primary melanocytes reduced the activities of both wild-type and oncogenic NRAS; conversely, ectopic expression of STK19 restored NRAS signaling. Silencing of STK19 inhibited colony formation and proliferation of oncogenic NRAS-transformed melanocytes in vitro and impaired their tumor formation in vivo. STK19 preferentially phosphorylated GTP-loaded active NRAS at S89, which was important for oncogenic NRAS-driven proliferation in melanocytes, as mutation of this residue inhibited colony formation, proliferation, and tumor formation. Several human patients with melanoma harbored mutant STK19 (D89N), which bound and activated NRAS more efficiently than wild-type STK19, suggesting that enhanced NRAS signaling caused by STK19 gain-of-function mutations is a driving event in human melanoma. Consistent with this possibility, in oncogenic NRAS-knockin mice, STK19 D89N expression resulted in hyperpigmentation and accelerated initiation and incidence of melanoma. A small compound library screen yielded a competitive inhibitor of STK19, ZT-12-037-01 (1a). In vitro, 1a inhibited phosphorylation of NRAS in time- and dose-dependent manners. Treatment of melanocytes with 1a impaired colony formation, proliferation, and xenograft tumor formation by inhibiting STK19-induced NRAS signaling. Treatment with 1a inhibited phosphorylation of both wild-type and oncogenic NRAS but triggered apoptosis in cells harboring oncogenic NRAS only. These deleterious effects of 1a were specific to inhibition of STK19, as expression of 1a-resistant STK19 mutants rescued oncogenic NRAS signaling. Collectively, these results identify STK19 as a kinase critical to oncogenic NRAS signaling in melanoma and present a means to target this refractory subtype of melanoma.

Yin C, Zhu B, Zhang T, Liu T, Chen S, Liu Y, et al. Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis. Cell 2019 Jan 31 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2019 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 9 (4)
April 2019
Volume 9, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacologic Inhibition of STK19 Impairs NRAS-Driven Melanoma
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pharmacologic Inhibition of STK19 Impairs NRAS-Driven Melanoma
Cancer Discov April 1 2019 (9) (4) OF8; DOI: 10.1158/2159-8290.CD-RW2019-017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Pharmacologic Inhibition of STK19 Impairs NRAS-Driven Melanoma
Cancer Discov April 1 2019 (9) (4) OF8; DOI: 10.1158/2159-8290.CD-RW2019-017
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • T-cell Receptor–Engineered T Cells Show Efficacy in HPV+ Carcinomas
  • Germline Genetic Variation Modulates Tumor Immune Microenvironment
  • Computational Analysis Finds Protein Stability–Related Cancer Mutations
Show more Research Watch

Melanoma

  • Midkine Promotes Immunosuppression and Reduces Immunotherapy Efficacy
  • Low-Heterogeneity Melanomas Are More Immunogenic and Less Aggressive
  • SMAD7 Loss Promotes Phenotype Switching–Independent Melanoma
Show more Melanoma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement